La cadena de opciones muestra datos clave de las opciones de acciones de Tilray Brands a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Tilray Brands..

Tilray Brands (NASDAQ:TLRY) Bolsa, Cadena de Opciones

Tilray Brands

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMPG

AVGR

BIPC

CHEK

CREV

FDSB

HSDT

KORE

LAES

LIND

NCRA

NEUE

NVNI

RELI

SLGL

TIVC

TLRY

TOVX

Carbon Revolution lidera con un aumento del 62,4% en el premercado. ¿Qué otras acciones destacaron antes de la apertura?

Las acciones de Carbon Revolution (CREV) están subiendo un 62%; 20 acciones que se están moviendo en el premercado

Tilray Brands Inc

<a href="https://www.marijuanamoment.net/trumps-pick-to-lead-dea-says-marijuana-rescheduling-review-will-be-one-of-my-first-priorities-in-the-job/" title="https://www.marijuanamoment.net/trumps-pick-to-lead-dea-says-marijuana-rescheduling-review-will-be-one-of-my-first-priorities-in-the-job/">https://www.marijuanamoment.net/trumps-pick-to-lead-dea-says-marijuana-rescheduling-review-will-be-one-of-my-first-priorities-in-the-job/</a>

Biotech

Macro Economic Events

Politics

Economics

General

AKAN

CRON

GRWG

IMCC

LFLY

MSOS

SNDL

"Trump's Pick To Lead DEA Says Marijuana Rescheduling Review Will Be 'One Of My First Priorities' In The Job" - Marijuana Moment

Tilray Brands' 10 Barrel Brewing Unveils NA Apocalypse IPA, Offering Bold, Hop-Driven Flavor Without The Alcohol

Author&#8217;s note: this article has been updated to include more context and commentary from analysts.
After months of sluggish performance, <a href="https://www.benzinga.com/cannabis">cannabis stocks</a> finally showed signs of life. This week, the U.S. cannabis sector surged double digits, fueled by new buzz around federal reform and the reemergence of an unlikely political player: Donald Trump.
The rally was led by the AdvisorShares Pure U.S. Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>), which jumped roughly 12.5% since Monday. At the time of publication, it had reclaimed its 50-day moving average for the first time since the 2024 election. But whether this move has real legs or is just another hype-fueled head fake depends on what happens next in Washington.
<h2 class="wp-block-heading">The Trump Factor</h2>
According to <a class="" href="https://themarijuanaherald.com/2025/04/president-trump-urging-congress-to-pass-marijuana-banking-bill-before-midterms-say-senate-staffers/">The Marijuana Herald</a>, President Trump is privately urging members of Congress to pass cannabis banking reform before the 2026 midterms. Two senior Senate staffers told the outlet that Trump began contacting lawmakers directly this week, encouraging them to prioritize the <a href="https://www.benzinga.com/topic/safer-banking-act">SAFER Banking Act</a> or similar legislation.
This follows earlier reporting—later confirmed by <a href="https://edition.cnn.com/2025/04/01/politics/trump-marijuana-ads/index.html">CNN</a>—that Trump's team tried to include SAFE banking language in a December 2024 funding resolution. While he hasn't made public comments since retaking office, Trump's campaign previously pledged to support "safe banking for state-authorized companies" and a move to reschedule marijuana for medical research.
No new banking bill has been introduced this session, but members of the Congressional Cannabis Caucus say it remains a top priority.
<h2 class="wp-block-heading">Legislative Winds Picking Up—But Not Moving Markets (Yet)</h2>
The STATES 2.0 Act, a bill that would formally defer cannabis policy to the states and end IRS 280E tax penalties, was reintroduced on April 17. But with no Senate companion and little immediate momentum, the bill didn't appear to influence stock prices. At best, it adds background noise to the growing chorus of reform chatter—but investors are still waiting for action, not aspiration.
<h2 class="wp-block-heading">A Technical Pop And A Cautious Crowd</h2>
"It was a Green Day on Wall Street," wrote Todd Harrison, founder of CB1 Capital, in his <a class="" href="https://substack.com/@toddharrison">Cannabis Confidential</a> newsletter of April 24. "Canna stocks were higher too as talk turned to promises made becoming promises kept."
Still, MSOS remains down 24% year-to-date, a reminder that breakouts in cannabis can fade as fast as they arrive. Harrison echoed that skepticism, noting that "no news is bad news" in a status quo world of "uneven regulations and onerous taxes."
He also referenced a recent White House visit from Weldon Angelos, a longtime advocate for cannabis clemency and reform, suggesting behind-the-scenes efforts are ramping up: "Suffice to say that if I was already of the view that promises made will be promises kept—I was—I feel better today than I did yesterday, despite still not having a line-of-sight on the timing."
Even so, he cautioned that many U.S. operators are still "racing against the clock" as tangible solutions to well-known issues—like tax burdens, banking access, custody restrictions and debt refinancing—remain elusive. 
"Tangible problems require tangible solutions, which are apparently on the way… but financial activity—restructurings, M&amp;A, equity movement—has largely ground to a halt."
<h2 class="wp-block-heading">Analysts Say Don't Chase It Just Yet</h2>
Viridian Capital Advisors struck a similar tone. In a client note, the firm acknowledged the optimism but warned against over-committing to rumors.
"Until Trump publicly states his support for SAFE banking and makes it more concrete than ‘before the midterms,' investors are right not to overcommit."
Viridian's analysis of U.S. MSOs with market caps between $50 million and $200 million shows the group still trades at a median EV/2025 EBITDA multiple of 4.57x, or 6.14x, when adjusted for lease and tax obligations. That signals potential value, but only if the policy tailwinds materialize.
"Recent news is causing some long-lost optimism," Viridian added. "Just don't drink all of the Kool-Aid in one gulp. Maintain dry powder to fill in positions on pullbacks."
<h2 class="wp-block-heading">Cannabis Stocks On The Move</h2>
Here&#8217;s how key cannabis stocks have performed this week so far:
<ul>
<li>Green Thumb Industries Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>): up almost 11%</li>
<li>Trulieve Cannabis Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>): up almost 29%</li>
<li>Curaleaf Holdings Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>): up 6.2%</li>
<li>Cronos Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>): up 5.4%</li>
<li>Tilray Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>): up 11%</li>
<li>Canopy Growth Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>): up 34.3%</li>
<li>SNDL Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>): up 7.5%</li>
<li>Glass House Brands Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GLASF#OTC">GLASF</a>): up 14.5%</li>
</ul>
<h2 class="wp-block-heading">The Bottom Line</h2>
Cannabis stocks rallied. Sentiment improved. Technicals woke up. But in this sector, headlines come cheap and real reform still costs political capital.
If SAFE banking re-emerges and Trump goes public with his support, this week's bounce could turn into something more meaningful. But until then, this may be just another puff of smoke in the long saga of cannabis policy and price action.
Photo: Shuttertock

Cannabis

CURLF

GLASF

GTBIF

TCNNF

Why Cannabis Stocks Jumped By Double Digits And Why Analysts Say 'Don't Drink The Kool-Aid In One Gulp'

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 138.10% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 41.36% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 36.62% at $0.11</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 22.50% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed up 20.33% at $4.67</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 20.17% at $1.49</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 18.63% at $0.78</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 18.06% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 17.33% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 16.57% at $6.19</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 14.10% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 12.99% at $8.35</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed up 12.83% at $0.42</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed up 11.74% at $0.49</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 9.14% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 8.47% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed up 7.78% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 7.33% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 7.26% at $0.97</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 6.81% at $0.20</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 6.74% at $0.99</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed up 6.67% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed up 6.45% at $4.71</li>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed up 6.29% at $0.26</li>
<li><a href="https://www.benzinga.com/quote/OGI">Organigram Global</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed up 5.56% at $1.16</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 5.43% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 5.26% at $0.49</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed up 4.92% at $1.48</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed up 4.50% at $8.65</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 3.97% at $1.31</li>
<li><a href="https://www.benzinga.com/quote/CRON">Cronos Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRON#NASDAQ">CRON</a>) shares closed up 3.35% at $1.85</li>
<li><a href="https://www.benzinga.com/quote/IIPR">Innovative Ind Props</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) shares closed up 3.09% at $53.38</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 93.81% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 11.81% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed down 9.17% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 4.60% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 4.17% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 3.33% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 3.15% at $0.80</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBRRF

CBDY

CLSH

CNBX

CNTMF

CPHRF

CRBP

CRLBF

CVSI

CXXIF

FUAPF

GBHPF

GNLN

IIPR

ITHUF

KAYS

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

LVRLF

MRMD

NWVCF

OILFF

RMHB

SOLCF

TGIFF

UGRO

XXII

YCBD

ZDPY

Cannabis Stock Movers For April 24, 2025

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed up 17.55% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 15.99% at $7.39</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed up 9.19% at $0.83</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed up 8.30% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 7.24% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 5.08% at $1.24</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 4.79% at $1.26</li>
<li><a href="https://www.benzinga.com/quote/CBDY">Target Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBDY#OTC">CBDY</a>) shares closed up 4.35% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 4.17% at $0.93</li>
<li><a href="https://www.benzinga.com/quote/OGI">Organigram Global</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed up 3.77% at $1.08</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed up 3.29% at $4.40</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ALEAF">Aleafia Health</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALEAF#OTC">ALEAF</a>) shares closed down 99.00% at $1e-06</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed down 40.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed down 35.48% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 28.57% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed down 22.37% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed down 22.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 20.00% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/MGWFF">Maple Leaf Green World</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MGWFF#OTC">MGWFF</a>) shares closed down 17.81% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 8.54% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 5.53% at $0.61</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 5.15% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 4.55% at $0.37</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 3.84% at $0.44</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 3.25% at $0.01</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALEAFIA HEALTH INC ORD by Aleafia Health Inc.

ALEAF

ELLXF

FFNTF

MGWFF

Bearish Sentiment Across The Cannabis Space - Check Full Movers For April 23, 2025

Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) launched a new whiskey expression under its acclaimed <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44945150/breckenridge-distillery-announces-re-release-of-award-winning-cognac-cask-finish-whiskey" rel="noreferrer noopener">Breckenridge Distillery</a><a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44945150/breckenridge-distillery-announces-re-release-of-award-winning-cognac-cask-finish-whiskey" rel="noreferrer noopener"> brand on Wednesday</a>.
The distillery unveiled the latest addition to its cask-finished lineup: Breckenridge Cognac Cask Finish Whiskey, which is available in Colorado with broader U.S. distribution anticipated later this year.
Originally released in 2022 as part of the second Collectors Art Series, this limited edition whiskey has returned with an elevated production run.
The label design honors its French barrel origins, featuring the iris—the national flower of France—and grape blossoms to acknowledge the Cognac region's heritage.
Bryan Nolt, founder and CEO of Breckenridge Distillery, emphasized the product's role in the company's innovation journey: "Our Cognac Cask Finish is a testament to our dedication to innovation and quality."
The new release will retail for $59.99.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44952395/us-business-activity-growth-slows-in-april-as-services-suffer-tariff-shock-markets-rally-as-trade-war-cools" rel="noreferrer noopener">Business Growth Cools, Prices Rise, And Markets Surge On Tariff Rollback Hopes</a>
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, TLRY stock has lost over 75% in the past year. Investors can gain exposure to the stock via&nbsp;AdvisorShares Pure Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YOLO#NYSE">YOLO</a>).
Earlier in April, the company announced plans to<a target="_blank" href="https://www.benzinga.com/news/25/04/44876284/tilray-stock-hit-a-new-52-week-low-today-whats-going-on" rel="noreferrer noopener">&nbsp;implement a reverse stock split.</a>
The move, subject to shareholder approval at a June 10 special meeting, proposes a split ratio between 1-for-10 and 1-for-20. This corporate action is aimed at boosting the per-share price and maintaining compliance with Nasdaq&#8217;s minimum listing requirements.
CEO&nbsp;Irwin Simon&nbsp;said the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44859783/tilray-brands-announces-proposed-reverse-stock-split-and-corresponding-special-meeting-of-stockhol" rel="noreferrer noopener">reverse split</a>&nbsp;will better align Tilray&#8217;s share count with peers and help stabilize trading. While the fundamentals remain intact, reverse splits are often perceived negatively by investors, as they can signal financial struggles or weak stock performance.
Price Action: TLRY shares are trading lower by 2.12% to %0.4482&nbsp;at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44948932/goldman-sachs-backs-copper-tariff-trade-if-trump-slaps-25-duty-on-us-imports" target="_blank" rel="noreferrer noopener">Goldman Sachs Backs ‘Copper Tariff Trade' If Trump Slaps 25% Duty On US Imports</a></li>
</ul>
Photo: Shutterstock

Equities

YOLO

What's Going On With Tilray Brands Stock Today?

Tilray's Breckenridge Distillery Unveils Cognac Cask Finish Whiskey, Plans U.S. Expansion

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 36.99% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 23.33% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 20.10% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 16.33% at $0.98</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 12.50% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 8.74% at $0.67</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 7.69% at $5.60</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 4.92% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed up 4.74% at $52.17</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 4.66% at $1.54</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 4.43% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 4.24% at $1.26</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 3.85% at $0.91</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed up 3.70% at $1.40</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 3.45% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 3.39% at $1.19</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 3.39% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed up 3.38% at $0.46</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed up 3.21% at $4.44</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 73.33% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 46.39% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 10.63% at $0.57</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 7.19% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 6.17% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 4.91% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 4.68% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 4.67% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 4.60% at $0.45</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 3.75% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 3.72% at $6.03</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLOZF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

Marijuana Stock Movers For April 18, 2025

From the halls of Congress to the streets of New York, cannabis news bloomed in every direction this week. Slovenia introduced what may become Europe's most progressive medical cannabis law. U.S. lawmakers filed new federal reform legislation. Trulieve and Curaleaf took diverging paths in Florida. And Governor Ron DeSantis faces questions over whether public funds were funneled into anti-cannabis campaigns.
Elsewhere, Weedmaps dropped a custom sneaker collab, Swatch&#8217;s 4/20-friendly watch returned to the spotlight and a massive new cancer study delivered groundbreaking validation for medical cannabis. Avicanna posted record earnings, Minnesota crossed a regulatory milestone and Blue Violets made delivery history in New Jersey.
Here's everything you need to know.
<h3 class="wp-block-heading">Business And Financial Moves</h3>
Avicanna Reports Record Year
Avicanna Inc. (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AVCN#TSX">AVCN</a>) (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/AVCNF#OTCQX">AVCNF</a>) reported audited financial results for 2024, including $25.5 million in revenue—a 52% increase over 2023—and gross profits of $12.9 million, up 94%. Consolidated gross margins improved to 51%, while adjusted EBITDA losses narrowed by 68% to $1.4 million. The company also repaid $1.3 million in debt.
CEO Aras Azadian called 2024 "our most successful year to date," citing clinical innovation, international expansion, and commercial growth in Canada and abroad.
Key 2024 milestones include:
<ul>
<li>A real-world evidence study in Canada evaluating cannabis for conditions like pain, sleep, anxiety and epilepsy</li>
<li>A completed study at The Hospital for Sick Children assessing CBD topical creams for wound healing</li>
<li>Drug approval in Colombia for Trunerox, targeting rare epileptic disorders</li>
<li>First delivery of CBD/CBG topicals to a multinational pharmaceutical company</li>
<li>Two new U.S. patents for topical and oral cannabinoid delivery technologies</li>
</ul>
<a href="https://www.benzinga.com/news/earnings/25/04/44802163/why-cannabis-focused-biopharma-co-avicanna-traded-up-26-today">Read the full story here</a>.
Tilray Plans Reverse Stock Split
Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) will hold a special shareholder meeting on June 10 to vote on a proposed reverse stock split ranging from 1-for-10 to 1-for-20. CEO Irwin Simon said the move aims to maintain Nasdaq compliance, reduce costs by more than $1 million per year, and attract institutional investors. The company recently reported over $248 million in cash and trimmed debt by $76 million.
<a href="https://www.benzinga.com/markets/cannabis/25/04/44871447/why-cannabis-co-tilray-tlry-is-trading-down-today">Read more on Benzinga</a>
Safe Harbor and FundCanna Join Forces
SHF Holdings, d/b/a Safe Harbor Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>), announced a strategic partnership with FundCanna to provide cannabis operators with streamlined access to capital and compliant banking services. The agreement enables mutual referrals and onboarding of FundCanna-approved clients into Safe Harbor-managed accounts.
"This partnership delivers a practical, scalable solution that puts the financial needs of cannabis operators first," said Safe Harbor CEO Terry Mendez.
<h3 class="wp-block-heading">Politics, Policy And Regulation</h3>
Congress Reintroduces STATES 2.0 Act
A bipartisan group of U.S. lawmakers reintroduced the STATES 2.0 Act, which would shield legal cannabis activity from federal interference. The bill would also legalize interstate commerce, normalize IRS treatment of cannabis businesses and establish a framework for federal oversight and testing.
"The current federal approach to cannabis policy is not working," said Rep. Dave Joyce (R-OH), co-chair of the Congressional Cannabis Caucus. "The STATES 2.0 Act creates a more logical approach that protects states' rights while improving public safety."
The bill maintains FDA oversight for cannabis products, removes barriers to tax deductions under Section 280E, and instructs federal agencies to begin rulemaking within 180 days of passage. Supporters include Reps. Max Miller (R-OH), Dina Titus (D-NV) and a coalition of advocacy organizations including CPEAR, Americans for Prosperity, and the U.S. Cannabis Roundtable.
<a class="" href="https://www.marijuanamoment.net">Read more via Marijuana Moment</a>
Minnesota Finalizes Adult-Use Cannabis Rules
The Minnesota Office of Cannabis Management (OCM) announced that final adult-use rules were published in the State Register and are now in effect. With this step completed, OCM can begin issuing business licenses to qualifying applicants, including more than 600 social equity applicants already advanced through preapproval.
"We are continuing to prioritize social equity in every stage of licensing," said Jess Jackson, OCM's director of social equity. Licenses for capped categories such as cultivator and retailer will be awarded via lottery later this summer, while uncapped license types will be distributed on a rolling basis.
<a class="" href="https://cannabis.mn.gov">Details available on the OCM Rulemaking page</a>
Slovenia Unveils Progressive Medical Cannabis Law
Slovenia's Parliament introduced sweeping medical cannabis reforms that would legalize the cultivation, production and distribution of cannabis for medical and scientific use. The bill eliminates public tenders, allows open licensing for private companies and removes cannabis and THC from the country's prohibited drugs list—so long as products meet GACP, GMP and European Pharmacopeia standards.
Cannabis will be available via standard medical or veterinary prescriptions, and patient access is guaranteed through pharmacies, licensed distributors and healthcare providers.
The legislation follows a 2024 referendum in which 66.7% of voters supported cannabis cultivation and legalization for medical use. According to ICBC, the new framework would position Slovenia as having the most advanced medical cannabis law in Europe.
<a class="" href="https://internationalcbc.com/slovenian-parliament-introduces-europes-most-progressive-medical-cannabis-law">Full article via ICBC</a>
DeSantis Faces Scrutiny Over Anti-Cannabis Funding
A Miami Herald investigation revealed that the DeSantis administration steered $10 million from a legal Medicaid settlement to a charity led by Florida First Lady Casey DeSantis. That charity then gave $5 million each to two organizations backing a political committee that opposed Amendment 3, the failed 2024 initiative to legalize adult-use cannabis in Florida.
The money flowed from the Hope Florida Foundation to Secure Florida's Future and Save Our Society from Drugs, which then routed millions to Keep Florida Clean, a DeSantis-aligned committee. Republican lawmakers are now demanding records and investigating whether public funds were improperly used to fight cannabis legalization.
<a class="" href="https://www.miamiherald.com/news/politics-government/article304020886.html">Full investigation by the Miami Herald</a>
<h3 class="wp-block-heading">State Moves And Brand Power Plays</h3>
Carmelo Anthony Launches STAYME7O In New York
Carmelo Anthony has entered the New York cannabis market with STAYME7O, a premium cannabis brand launched in partnership with Grand National, the creative agency he co-founded with Jesce Horton and Brandon Drew Jordan Pierce. The product line features curated flower cultivated by Oregon-based LOWD, with an emphasis on sustainability and unique genetics.
"This isn't just about cannabis—it's about empowering our communities," Anthony said. A portion of proceeds will support NuProject and the Last Prisoner Project, continuing the brand's focus on economic equity and justice reform.
<a class="" href="https://www.benzinga.com/general/sports/25/04/44801792/carmelo-anthony-enters-new-york-cannabis-market-all-about-his-product-line-and-creative-agency">Full story on Benzinga</a>
Curaleaf Turns Dispensary Into Hemp Shop
Curaleaf (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) has converted one of its medical dispensaries in West Palm Beach into a hemp-focused retail store called The Hemp Company. The location will offer Farm Bill-compliant THC products from Curaleaf brands and partners like 1906 and Cann.
The move comes as Curaleaf distances itself from Florida's stalled adult-use push and signals short-term interest in the rapidly growing hemp-derived THC segment.
Trulieve Invests $19.6M To Revive Legalization Push
Trulieve (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) contributed $19.6 million to Smart &amp; Safe Florida to support another attempt at adult-use legalization in 2026. That's in addition to the $145 million the company spent on the failed 2024 initiative.
So far, only 150,804 signatures have been verified out of the 880,062 needed to qualify for the next ballot, raising questions about whether other operators will step in to help fund the campaign.
Herbwell Cannabis Targets Manhattan's Elite
Herbwell, a national cannabis chain, is opening a luxury dispensary at 519 Madison Avenue—possibly the only one of its kind on the high-end Manhattan corridor. The shop promises a curated experience for both seasoned users and curious first-timers.
"We've built a gorgeous dispensary that fits in on Madison Avenue," said CEO Arish Halani. "One day we'll be doing collabs with the biggest brands in the world."
The brand is also planning to open a cannabis club in the building's upper floors, including a rooftop lounge overlooking Midtown, pending future regulations.
New Jersey's First E-Bike Weed Delivery
Hoboken dispensary Blue Violets has launched New Jersey's first cannabis delivery service by e-bike, in partnership with delivery tech company Priscotty. The program is live in Hoboken and parts of Jersey City and Weehawken.
"We want to reach our customers when they can't make their way to the store—but in a way that makes sense," said Lauren Thompson, co-owner of Blue Violets.
<h3 class="wp-block-heading">Culture And Commentary</h3>
Mike Tyson Becomes CEO Of Carma HoldCo
Boxing legend Mike Tyson has taken the reins as CEO of Carma HoldCo, the company behind TYSON 2.0, Ric Flair Drip, Evol by Future and Wooooo! Energy. The move marks Tyson's shift from brand ambassador to active executive, steering a portfolio built on cultural storytelling and celebrity power.
"This isn't just a title—it's a responsibility I take seriously," Tyson said. Under his leadership, Carma plans to double down on authenticity, community engagement and global expansion.
<a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44871633/mike-tyson-cannabis-ceo-the-champ-now-runs-carma-holdco">Read the full story on Benzinga</a>
Weedmaps Drops 420 1's Sneaker Collab With CEEZE
In one of the most buzzworthy 4/20 drops of the year, Weedmaps and custom sneaker studio CEEZE released the limited-edition "420 1's." Each of the 420 pairs is individually numbered, housed in an acrylic box with LED lighting and linked to a microsite via QR code.
The Friends &amp; Family version even includes GPS coordinates pointing to the historic San Francisco Cannabis Buyers Club. A sweepstakes is running through April 20, offering 20 pairs and one VIP trip to Spannabis.
<a class="" href="https://weedmaps.com/wm-sneakers-420-1s">Details and entry here</a>
Swatch's 4/20 Watch Gets a Second Life
Swatch's "Up In Smoke" watch from 2024 has found new life this April. With minty green hues, smoke-dial graphics and a laid-back BIOCERAMIC case, the piece fits right into the 4/20 aesthetic. Originally part of the BIG BOLD collection, the watch has quietly become a seasonal flex for cannabis aficionados.
<a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44878425/swatchs-up-in-smoke-watch-is-the-low-key-flex-of-4-20-season">Read the full feature on Benzinga</a>
Dreka Gates, Tiffany Haddish And Chamath Sound Off
Cannabis was also front and center in this week's cultural commentary. Highlights include:
<ul>
<li>Dreka Gates, in an exclusive interview, said: "Cannabis would be a trillion-dollar industry for Black and Brown communities—if it hadn't been criminalized." <a class="" href="https://www.benzinga.com/markets/cannabis/25/04/39798605/dreka-gates-cannabis-would-be-a-trillion-dollar-industry-for-black-and-brown-communities-if-it-h">Read more</a></li>
<li>Tiffany Haddish remarked that "If men had period pain, weed would already be legal." <a class="" href="https://www.benzinga.com/markets/cannabis/25/04/39797136/tiffany-haddish-if-men-had-period-pain-weed-would-already-be-legal">Full story here</a></li>
<li>Chamath Palihapitiya criticized the industry, saying legalization "turned our kids into zombies." <a class="" href="https://www.benzinga.com/general/health-care/25/04/44831042/chamath-palihapitiya-calls-for-mandate-on-insidious-marijuana-labelling-and-toxicity-says-its-turning-kids-into-zombies">His take here</a></li>
</ul>
<h3 class="wp-block-heading">Science And Health</h3>
Landmark Study Confirms Cannabis Benefits for Cancer Patients
In what may be the most comprehensive review of its kind, Cancer Playbook and the Whole Health Oncology Institute published a meta-analysis of over 10,000 peer-reviewed studies on medical cannabis and cancer. The result: a 3-to-1 scientific consensus in favor of cannabis for treating cancer-related symptoms, including inflammation, metastasis, appetite loss and pain.
"We expected controversy. What we found was overwhelming scientific consensus," said Ryan Castle, WHOI's head of research.
The study also incorporated patient-reported outcomes to highlight real-world effectiveness—marking a shift toward more holistic, experience-driven research models. Findings from this report were submitted to the DEA as part of the case for rescheduling cannabis.
<a class="" href="https://www.benzinga.com/general/health-care/25/04/44835610/game-changing-study-confirms-medical-cannabis-helps-cancer-patients-we-found-overwhelming-scientific-consensus">Link to the full Benzinga article</a>
Israel Slaps 165% Tariffs on Canadian Cannabis
In a dramatic turn, Israel's Ministry of Economy announced it will impose tariffs of up to 165% on Canadian cannabis imports for the next four years. The decision—pending approval by the Knesset Finance Committee—carves out exceptions for select producers like Decibel (12%), Village Farms (28%), Organigram (53%) and Tilray (70%).
The move signals a potential realignment of the global cannabis trade, with implications for both exporters and Israeli medical patients.
<a class="" href="https://stratcann.com">More via StratCann</a>
<h3 class="wp-block-heading">Recommended Reads</h3>
<ul>
<li><a class="" href="https://www.forbes.com/sites/javierhasse/2025/04/14/he-sold-his-cannabis-vape-brand-for-nine-figures-now-hes-coming-for-your-cocktail/">He Sold His Cannabis Vape Brand for Nine Figures—Now He's Coming for Your Cocktail</a></li>
<li><a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44818968/how-one-european-company-is-flooding-america-with-cannabis-seeds">How One European Company Is Flooding America With Cannabis Seeds</a></li>
</ul>
That&#8217;s it for this week. See you next Friday!

Earnings

AVCNF

SHF Holdings, Inc. - Class A Common Stock

SHFS

TSX:AVCN

This Week In Cannabis: Carmelo's NY Launch, Federal Reform, Cancer Study, Avicanna's Growth, Tilray's Split, DeSantis Fallout, Slovenia's Big Move And More

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 36.99% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ELLXF">Elixinol Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ELLXF#OTC">ELLXF</a>) shares closed up 23.33% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed up 20.10% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/FUAPF">Global Compliance</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FUAPF#OTC">FUAPF</a>) shares closed up 12.50% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed up 11.21% at $3.87</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 8.74% at $0.67</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed up 7.69% at $5.60</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed up 5.63% at $0.23</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 4.92% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed up 4.74% at $52.17</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 4.43% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed up 3.85% at $0.91</li>
<li><a href="https://www.benzinga.com/quote/SNDL">SNDL</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDL#NASDAQ">SNDL</a>) shares closed up 3.70% at $1.40</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 3.45% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed up 3.39% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/BLOZF">Cannabix Technologies</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BLOZF#OTC">BLOZF</a>) shares closed up 3.38% at $0.46</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 73.33% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed down 46.39% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed down 8.70% at $0.57</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 7.19% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed down 6.17% at $0.17</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 5.11% at $0.45</li>
<li><a href="https://www.benzinga.com/quote/CVSI">CV Sciences</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CVSI#OTC">CVSI</a>) shares closed down 4.91% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 4.68% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 4.67% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed down 3.82% at $0.58</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed down 3.75% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 3.72% at $6.03</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis Stock Movers For April 17, 2025

Tilray Brands Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares are trading lower by 6.2% to 45 cents during Thursday&#8217;s session. The company on Thursday announced plans to <a href="https://www.benzinga.com/markets/cannabis/25/04/44871447/why-cannabis-co-tilray-tlry-is-trading-down-today">implement a reverse stock split</a>. 
What To Know: The move, subject to shareholder approval at a June 10 special meeting, proposes a split ratio between 1-for-10 and 1-for-20. This corporate action is aimed at boosting the per-share price and maintaining compliance with Nasdaq's minimum listing requirements.
CEO Irwin Simon said the <a href="https://www.benzinga.com/pressreleases/25/04/g44859783/tilray-brands-announces-proposed-reverse-stock-split-and-corresponding-special-meeting-of-stockhol">reverse split</a> will better align Tilray's share count with peers and help stabilize trading. While the fundamentals remain intact, reverse splits are often perceived negatively by investors, as they can signal financial struggles or weak stock performance.
Read Also: <a href="https://www.benzinga.com/25/04/44869117/whats-going-on-with-faraday-future-stock-thursday">What&#8217;s Going On With Faraday Future Stock Thursday?</a>
Though the split doesn't affect the company's market cap, it reduces the number of outstanding shares.
What Else: Tilray says the company expects over $1 million in annual cost savings from the measure and continues to emphasize its financial strength, including a recent $76 million debt reduction and $248 million in cash and marketable securities.
Despite Thursday&#8217;s volatility, Tilray also announced Thursday that the company is expanding globally, with <a href="https://www.benzinga.com/pressreleases/25/04/g44861025/tilray-medical-introduces-cannabis-edibles-in-australia">new cannabis edibles</a> in Australia and a U.S. launch of "Cruisies," its <a href="https://www.benzinga.com/pressreleases/25/04/g44861775/tilray-beverages-launches-cruisies-a-new-line-of-ready-to-drink-cocktails">summer-ready cocktail line</a>.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44873779/wall-street-rebounds-eli-lilly-rallies-unitedhealth-group-plummets-whats-driving-markets-thursday">Wall Street Rebounds, Eli Lilly Rallies, UnitedHealth Group Plummets: What&#8217;s Driving Markets Thursday?</a>
<h2 class="wp-block-heading">How To Buy TLRY Stock</h2>
By now you're likely curious about how to participate in the market for Tilray Brands &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Tilray Brands, which is trading at $0.45 as of publishing time, $100 would buy you 222.22 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TLRY has a 52-week high of $2.52 and a 52-week low of $0.43.

Tilray Stock Hit A New 52-Week Low Today: What's Going On?

Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares slipped 6.8% on Thursday afternoon after the <a href="https://www.benzinga.com/cannabis">cannabis</a> and beverage company proposed a reverse stock split that would significantly reduce its number of shares outstanding.
In a notice to investors, <a href="https://www.benzinga.com/topic/tilray">Tilray</a> said it would hold a special shareholder meeting on June 10 to vote on amending its certificate of incorporation to enable a reverse split in a range of 1-for-10 to 1-for-20. The exact ratio would be selected by the company's board.
CEO Irwin Simon framed the move as part of a broader effort to maintain Tilray's Nasdaq listing, stabilize share prices, attract institutional investors, and reduce administrative costs.
"A higher price per share would ensure compliance with Nasdaq&#8217;s continued listing requirements and places Tilray in a position to continue executing on our strategic plans," Simon said in a statement. "We expect this decision to aid in the Company's efforts to stabilize trading levels, attract and retain institutional shareholders, and decrease our cost structure by over $1 million on an annual run rate basis."
While reverse stock splits can help struggling stocks regain compliance or investor attention, they often trigger short-term selloffs due to concerns about dilution or underlying financial health.
Also read: <a href="https://www.benzinga.com/news/earnings/25/04/44802163/why-cannabis-focused-biopharma-co-avicanna-traded-up-26-today">Why Cannabis-Focused Biopharma Co. Avicanna Traded Up 26%+ Today</a>
Despite Tuesday's drop, Tilray emphasized its improved financial position, citing a $76 million reduction in debt year-to-date and a cash and marketable securities balance of over $248 million as of February 28, 2025. The company says its net debt to EBITDA ratio is now below 1.0x, a strong sign of fiscal stability.
In a separate announcement Tuesday, Tilray also shared that it has expanded its medical cannabis product line in Australia, launching Good Supply Pastilles — its first edibles offering for patients in that market. The sugar-free, vegan-friendly products come in THC10, THC10:CBD10, and CBD20 varieties.
"The expansion of our medical cannabis portfolio with the introduction of Good Supply Pastilles in Australia is a significant milestone," said Denise Faltischek, Tilray's chief strategy officer and head of international. "We are committed to providing high-quality, accessible medical cannabis products in convenient formats to patients worldwide."
Photo: Shutterstock

Why Cannabis Co. Tilray (TLRY) Is Trading Down Today

Tilray Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>), through its healthcare-focused arm Tilray Medical, has rolled out its <a href="https://www.benzinga.com/pressreleases/25/04/g44861025/tilray-medical-introduces-cannabis-edibles-in-australia">inaugural range of cannabis-infused medical</a> edibles in Australia. 
This development represents an important advancement in the firm's international growth efforts and enhances access to alternative, plant-derived treatment choices for patients.
Tilray Medical has launched its Good Supply Pastilles, a line of sugar-free, vegan-friendly edibles, now available to patients across Australia.
The new product range includes three variants: Good Supply Pastilles THC10 (Strawberry), THC10 CBD10 (Pineapple), and CBD20 (Raspberry). 
Also Read: <a href="https://www.benzinga.com/trading-ideas/dividends/25/04/44863342/retail-giant-costco-raises-dividend-by-12">Retail Giant Costco Raises Dividend By 12%</a>
&#8220;Our dedication to innovation and patient care drives us to continuously expand our offerings, ensuring that patients receive the best possible treatment options tailored to meet their needs and preferences,&#8221; said Chief Strategy Officer and Head of International, Denise Faltischek.
&#8220;The expansion of our medical cannabis portfolio with the introduction of Good Supply Pastilles in Australia is a significant milestone for Tilray Medical. We are committed to providing high-quality, accessible medical cannabis products in convenient formats to patients worldwide.&#8221;
Patients can purchase packs containing 60 pastilles through Tilray Direct or from licensed medical cannabis providers.
Tilray offers a wide range of THC and CBD products in over 20 countries and supports international clinical research on cannabis treatments.
Tilray Brands is a global lifestyle and consumer goods company with a focus on cannabis, beverages, wellness, and entertainment. Tilray&#8217;s products include cannabis, hemp foods, and craft beverages.
Price Action: TLRY shares traded lower by 6.58% at $0.44 at last check Thursday. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44850301/target-under-pressure-from-discretionary-spend-slowdown-mounting-inventory-risk-goldman-sachs-downgrades-stock">Target Under Pressure From Discretionary Spend Slowdown, Mounting Inventory Risk, Goldman Sachs Downgrades Stock</a></li>
</ul>
Photo: Cannabis_Pic/Shutterstock

Vegan, Sugar-Free, And Now In Australia: Tilray's Edibles Aren't Your Average Medical Launch

<a href="https://www.marijuanamoment.net/bipartisan-congressional-lawmakers-file-bill-to-end-federal-marijuana-prohibition-in-legal-states-in-line-with-trumps-stance/" title="https://www.marijuanamoment.net/bipartisan-congressional-lawmakers-file-bill-to-end-federal-marijuana-prohibition-in-legal-states-in-line-with-trumps-stance/">https://www.marijuanamoment.net/bipartisan-congressional-lawmakers-file-bill-to-end-federal-marijuana-prohibition-in-legal-states-in-line-with-trumps-stance/</a>

MAPS

'Bipartisan Congressional Lawmakers File Bill To End Federal Marijuana Prohibition In Legal States In Line With Trump's Stance' - Marijuana Moment

WIIM

Tilray Brands shares are trading lower after the company announced it will vote to implement a reverse stock split, potentially upwards of a 1-to-20 basis.

SYDNEY, April 17, 2025 (GLOBE NEWSWIRE) -- Tilray Medical ("Tilray"), a division of Tilray Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#TSX">TLRY</a>), a global company in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, has announced the availability of its medical cannabis edibles, Good Supply Pastilles, to patients in Australia. This launch marks Tilray Medical's first medical cannabis edible offering in the country, providing patients with a sugar-free and vegan-friendly treatment option.
Denise Faltischek, Chief Strategy Officer and Head of International, Tilray Brands, stated, "Our dedication to innovation and patient care drives us to continuously expand our offerings, ensuring that patients receive the best possible treatment options tailored to meet their needs and preferences. The expansion of our medical cannabis portfolio with the introduction of Good Supply Pastilles in Australia is a significant milestone for Tilray Medical. We are committed to providing high-quality, accessible medical cannabis products in convenient formats to patients worldwide."
Good Supply Pastilles are available in the following options:
<ul>
<li>Good Supply Pastilles THC10 (Strawberry)</li>
<li>Good Supply Pastilles THC10 CBD10 (Pineapple)</li>
<li>Good Supply Pastilles CBD20 (Raspberry) &nbsp;</li>
</ul>
Medical cannabis patients are now able to purchase the Good Supply Pastilles in packs of 60 from Tilray Direct or their local medical cannabis distributors.
Tilray continues to be a leading provider of EU-GMP certified medical cannabis to patients, physicians, pharmacies, hospitals, governments, and researchers globally. Today, Tilray offers a comprehensive portfolio of THC and CBD products in over 20 countries, supporting medical trials worldwide to study the efficacy of medical cannabis for various conditions.

TSX:TLRY

Tilray Medical Announces Availability Of Medical Cannabis Edibles, Good Supply Pastilles, To Patients In Australia

Stock Split

Tilray Brands To Vote For Implementation Of Reverse Stock Split At A Ratio Ranging From 1-to-10 To 1-to-20

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/ALEAF">Aleafia Health</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ALEAF#OTC">ALEAF</a>) shares closed up 900.00% at $1e-05</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed up 31.84% at $0.10</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 21.33% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 15.18% at $0.57</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed up 14.62% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 9.62% at $0.06</li>
<li><a href="https://www.benzinga.com/quote/CGC">Canopy Gwth</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGC#NASDAQ">CGC</a>) shares closed up 9.36% at $0.94</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 8.27% at $0.15</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 8.21% at $0.19</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed up 6.38% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed up 6.15% at $6.04</li>
<li><a href="https://www.benzinga.com/quote/OGI">Organigram Global</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed up 5.57% at $1.03</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed up 5.26% at $0.60</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed up 5.26% at $0.80</li>
<li><a href="https://www.benzinga.com/quote/RIV">Rivernorth Opps Fund</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#NYSE">RIV</a>) shares closed up 4.86% at $10.81</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 4.17% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed up 4.14% at $4.28</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 3.68% at $1.41</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/GBHPF">Global Hemp Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GBHPF#OTC">GBHPF</a>) shares closed down 56.27% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed down 26.09% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 10.34% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 6.55% at $0.89</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed down 4.67% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 4.65% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 3.56% at $0.49</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed down 3.19% at $4.90</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 3.14% at $0.27</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARA

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CWBHF

Cannabis Stock Gainers And Losers From April 11, 2025

Another busy stretch reminded the cannabis industry that momentum rarely moves in a straight line. 
Minnesota punted its adult‑use launch to at least 2026, while Germany's new coalition left legalization intact. In Latin America, Chile pushed a sweeping adult‑use bill even as Panama tightened medical rules and Italy stunned hemp operators with a sudden ban. 
Companies stayed active: SNDL Inc. (NASDAQ: SNDL) inked a 32‑store acquisition and started trading in Canada, MariMed Inc. (OTC: MRMD) elevated a longtime brand builder to chief commercial officer and Tilray Brands Inc. (NASDAQ: TLRY) trimmed guidance after softer cannabis sales. 
Below is a recap of every headline that mattered.
<h2 class="wp-block-heading">Politics And Regulation</h2>
<h3 class="wp-block-heading">U.S. Rescheduling Could Drift Under Trump</h3>
Former DEA adviser Matt Lawrence told an Ohio State University forum that, without explicit White House backing, the DEA might "do essentially nothing at all," leaving the Schedule III proposal in limbo. Former HHS counsel Patricia Zettler added that new DEA nominee Terrance Cole's long agency tenure "doesn't bode particularly well for support of rescheduling," warning that the simplest outcome may be prolonged delay.
The discussion, reported by <a class="" href="https://www.marijuanamoment.net/former-dea-and-hhs-officials-suggest-marijuana-rescheduling-could-be-delayed-indefinitely-if-trump-doesnt-proactively-support-it/">Marijuana Moment</a>, highlighted how politics—not science—will likely dictate the timetable. Speakers also noted that DEA could revive the process quickly if President Trump deems it a priority, but the administration's first‑year drug plan omitted any reference to cannabis reform.
<h3 class="wp-block-heading">Medicare And Medicaid Draw A Hard Line</h3>
The Centers for Medicare &amp; Medicaid Services finalized a rule clarifying that "alcohol, tobacco, and cannabis products" are ineligible as supplemental benefits in Medicare Advantage plans. CMS said it had fielded questions about covering medical marijuana but reiterated that cannabis remains illegal federally.
In the same notice—slated for the Federal Register on June 3—CMS specified that CBD products also fail the "primarily health related" test, effectively barring coverage. The policy details appear in the agency's rulemaking summary, also covered by <a class="" href="https://www.marijuanamoment.net/medicare-and-medicaid-officials-finalize-rule-to-clarify-that-medical-marijuana-isnt-covered-by-federal-health-programs/">Marijuana Moment</a>.
<h3 class="wp-block-heading">Minnesota's Retail Clock Slips</h3>
Consultant Stefan Egan, who helped draft Minnesota's adult‑use law, told <a class="" href="https://kstp.com/kstp-news/top-news/minnesota-marijuana-dispensaries-might-not-open-until-late-spring-2026/">KSTP‑TV</a> that absent final rules, licenses won't be issued before late spring 2026. Sen. Mark Koran projected another nine to twelve months for build‑outs and product testing, pushing first sales into late spring or early summer 2026.
Both sources warned that uncertainty hampers investment. The Office of Cannabis Management noted more than 1,000 qualified applicants stand ready once regulations land, but it offered no firm timeline.
<h3 class="wp-block-heading">Germany Keeps CanG in Place</h3>
Germany's new CDU/CSU‑SPD coalition will not roll back the 2024 legalization law. Instead, the government plans a "neutral evaluation" in autumn 2025.
The compromise came after Bavaria's CSU pushed for reinstating prohibition. Federal drug commissioner Burkhard Blienert called the existing framework "an important contribution to a more honest and decriminalized approach to drugs," urging patience until the review.
Read the full story on <a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44716802/cannabis-stays-legal-in-germany-following-new-coalition-deal">Benzinga</a>
<h3 class="wp-block-heading">Chile Advances Adult‑Use Bill</h3>
A cross‑party coalition introduced legislation allowing six‑plant home‑grows, 40‑gram public possession and nonprofit cultivation clubs. Lead sponsor Ana María Gazmuri said the proposal "allows us to catch up with international standards."
Civil‑society leaders told El Planteo the bill addresses organized crime by offering legal access. Presidential contender Vlado Mirosevic pledged to champion legalization if elected, calling prohibition a "failure of drug policy."
Read the full story on <a href="https://www.benzinga.com/news/legal/25/04/44743798/chile-moves-to-legalize-adult-use-cannabis-with-backing-from-presidential-candidate">Benzinga</a>
<h3 class="wp-block-heading">Panama Regulates, Italy Prohibits</h3>
Panama's Decree No. 6 broadens physician prescribing rights but bans vaporizers, a restriction reformer Carlos Ossa called illogical because "70% of patients use vaporizers." Production licenses remain pending, so the country still relies on imports.
Only a few days before that, Italy issued an emergency decree banning all hemp and CBD flowers. Trade group Canapa Sativa Italia warned the move threatens up to 30,000 jobs and violates EU precedent that CBD is not a narcotic.
Read the full story on <a href="https://www.benzinga.com/markets/cannabis/25/04/44747982/one-step-forward-one-step-back-panama-regulates-cannabis-italy-bans-it">Benzinga</a>.
<h3 class="wp-block-heading">Netherlands Launches Supply‑Chain Pilot</h3>
Ten municipalities—including Arnhem, Groningen and Tilburg—began requiring coffeeshops to stock only state‑licensed cannabis. Hashish will follow once supply stabilizes, officials told Dutch media. Shop owner Willem Vugs welcomed the phased roll‑out, saying growers need time to "produce the right quality and variety."
The four‑year experiment, detailed by Dutch News reporting, aims to replace the decades‑old "back‑door" model where sales are tolerated but large‑scale cultivation remains illegal.
<h2 class="wp-block-heading">Corporate And Market Moves</h2>
<h3 class="wp-block-heading">SNDL Expands Retail Footprint And Lists On The CSE</h3>
SNDL Inc. agreed to buy 32 Cost Cannabis and T Cannabis stores from 1CM Inc. (CSE: EPIC) for C$32.2 million in cash, per the companies' joint release. CEO Zach George said the deal "aligns with our stated capital priorities" and boosts the network to 219 owned or franchised outlets.
The transaction—covering locations in Ontario, Alberta and Saskatchewan—generated C$53 million in revenue for 1CM's fiscal 2024. Closing is expected by Q3 2025, pending court and shareholder approval, after which 1CM plans to return "a substantial portion" of the proceeds to investors.
Two days after the acquisition announcement, SNDL began trading on the Canadian Securities Exchange under the same ticker. George said the move "creates optionality for shareholders" and positions the company to pursue growth with "greater agility."
The CSE listing allows investors to trade shares in Canadian dollars and fits the exchange's cannabis‑friendly framework, according to SNDL's statement.
<h3 class="wp-block-heading">MariMed Names Chief Commercial Officer</h3>
MariMed Inc. promoted Ryan Crandall—co‑creator of Betty's Eddies Chews—to chief commercial officer. CEO Jon Levine credited Crandall with building "our innovative and trusted portfolio of brands."
Crandall, who joined MariMed in 2018, will oversee sales, marketing, product development and retail. He called the role "a fantastic journey" and pledged to strengthen MariMed's market position.
<h3 class="wp-block-heading">Scotts Miracle‑Gro Spins Off Hawthorne Collective</h3>
The Scotts Miracle‑Gro Company (NYSE: SMG) transferred its Hawthorne Collective investment arm to an independent partner in exchange for an interest‑bearing note. CEO Jim Hagedorn said the move reduces cannabis‑sector volatility and lets Scotts focus on core lawn and garden products.
The company retains an option to reacquire Hawthorne Collective if federal reform—such as rescheduling or the SAFER Banking Act—boosts sector prospects. Hagedorn noted that "four years of unkept promises" have hampered growth.
<h3 class="wp-block-heading">Tilray Trims Revenue Outlook</h3>
Tilray Brands reported Q3 revenue of $185.8 million, down from $188.3 million a year earlier and below consensus. Cannabis sales fell to $54.3 million, while beverage alcohol rose slightly to $55.9 million.
Citing SKU rationalization and a shift of product from Canada to higher‑margin export markets, Tilray cut its FY‑2025 revenue target to $850–900 million from up to $1 billion, as detailed in <a class="" href="https://www.benzinga.com/25/04/44685827/tilray-brands-reports-lower-cannabis-sales-in-q3-trims-2025-revenue-outlook">Benzinga</a>.
<h2 class="wp-block-heading">Market Forecasts</h2>
<h3 class="wp-block-heading">Whitney Economics Slashes U.S. Sales Projections</h3>
Data firm Whitney Economics reduced its 2025–2030 U.S. retail forecast by $21.1 billion, blaming oversupply, high taxes and hemp‑derived substitutes. Founder Beau Whitney said, "Lower prices, lower participation and more substitutes will result in lower revenues."
California took the biggest hit, with a $606 million downgrade for 2025. New York and Maryland were bright spots, reflecting faster‑growing new markets. 
Read the full story on <a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44720279/is-legal-weed-in-trouble-analyst-says-taxes-oversupply-and-hemp-threat-drove-a-21b-cut-in-sales-estimates">Benzinga</a>.
<h2 class="wp-block-heading">Science, Education &amp; Events</h2>
<h3 class="wp-block-heading">Avicanna Calls Clinicians To Toronto</h3>
Avicanna Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AVCNF#OTC">AVCNF</a>) (TSX: AVCN) will host its fifth medical symposium—"From Emerging Evidence to Clinical Practice"—on June 6 at Toronto's MaRS Discovery District. Executive VP Dr. Karolina Urban said the gathering aims to "enhance our collective understanding of cannabinoid‑based medicines."
Speakers include researchers from Washington State, Johns Hopkins and the University of British Columbia, covering topics from CBG's therapeutic potential to opioid–cannabinoid interactions. Healthcare professionals can register or submit poster abstracts at <a class="" href="https://www.avicanna.com/symposium">avicanna.com/symposium</a>.
<h3 class="wp-block-heading">Argentina Explores Cannabis Tourism And Chemo Pain Relief</h3>
Mendoza passed a law creating a provincial cannabis registry, while entrepreneur Gonzalo Llamas Bianchetti's Proyecto Vallecitos seeks to revive an abandoned ski town with hemp‑based eco‑lodging and cultivation. Provincial health leader Daniel Llaver said the registry focuses on patient access and industry compliance.
Separately, a three‑year preclinical study by CONICET and Universidad Austral found a 1:1 CBD‑THC oral blend prevented chemotherapy‑induced neuropathic pain in rats without added toxicity. Both stories were detailed in <a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44745709/from-malbec-to-marijuana-argentinas-provincial-push-fuels-cannabis-tourism-science-and-policy">Benzinga</a>.
<h2 class="wp-block-heading">Recommended Reads Of The Week</h2>
<ul>
<li><a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44720917/whos-blocking-cannabis-reform-in-the-senate-marijuana-policy-remains-a-dividing-line-between-democrats-and-republicans">Who's Blocking Cannabis Reform in the Senate?</a></li>
<li><a class="" href="https://www.benzinga.com/markets/cannabis/25/04/44752007/latino-entrepreneurs-are-thriving-in-nycs-cannabis-market-heres-the-proof">Latino Entrepreneurs Are Thriving in NYC's Cannabis Market—Here's the Proof</a></li>
<li><a class="" href="https://www.forbes.com/sites/javierhasse/2025/04/08/ice-t-says-he-doesnt-get-high-so-why-did-he-open-a-cannabis-dispensary-with-a-playboy-playmate/">Ice‑T Says He Doesn't Get High—So Why Did He Open a Cannabis Dispensary With a Playboy Playmate?</a></li>
</ul>
Check back next week for a new recap of what&#8217;s going on in the most exciting industry in the world. Until then, stay high(drated).

The Week In Cannabis: Delays, Decrees And Deals Reshape The Global Playbook

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 35.29% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/UGRO">Urban-gro</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) shares closed up 22.70% at $0.50</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 11.07% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed up 10.47% at $0.14</li>
<li><a href="https://www.benzinga.com/quote/ITHUF">iAnthus Capital Hldgs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ITHUF#OTC">ITHUF</a>) shares closed up 9.09% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/KAYS">Kaya Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/KAYS#OTC">KAYS</a>) shares closed up 7.59% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/SOL">Emeren Group</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOL#NYSE">SOL</a>) shares closed up 4.35% at $1.36</li>
<li><a href="https://www.benzinga.com/quote/VFF">Village Farms Intl</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) shares closed up 4.19% at $0.51</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 4.00% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/RIV">Rivernorth Opps Fund</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIV#NYSE">RIV</a>) shares closed up 3.60% at $10.71</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/CNGGF">Cann Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNGGF#OTC">CNGGF</a>) shares closed down 55.23% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 15.00% at $0.95</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Glb Inv</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 11.56% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 8.09% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/CPHRF">Cipher Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CPHRF#OTC">CPHRF</a>) shares closed down 6.48% at $7.72</li>
<li><a href="https://www.benzinga.com/quote/IIPR">Innovative Ind Props</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) shares closed down 5.98% at $48.70</li>
<li><a href="https://www.benzinga.com/quote/MRMD">MariMed</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>) shares closed down 4.82% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 4.30% at $0.51</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 4.26% at $0.26</li>
<li><a href="https://www.benzinga.com/quote/SMG">Scotts Miracle Gro</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) shares closed down 4.13% at $50.42</li>
<li><a href="https://www.benzinga.com/quote/MXC">Mexco Energy</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MXC#AMEX">MXC</a>) shares closed down 4.00% at $7.20</li>
<li><a href="https://www.benzinga.com/quote/ACB">Aurora Cannabis</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACB#NASDAQ">ACB</a>) shares closed down 3.98% at $4.11</li>
<li><a href="https://www.benzinga.com/quote/CARA">Cara Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares closed down 3.88% at $4.87</li>
<li><a href="https://www.benzinga.com/quote/LVRLF">CordovaCann</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LVRLF#OTC">LVRLF</a>) shares closed down 3.68% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/ESE">ESCO Technologies</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESE#NYSE">ESE</a>) shares closed down 3.24% at $147.00</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CNGGF

Cannabis Stock Gainers And Losers From April 10, 2025

Press Releases

10 Barrel Brewing Co. and Scout Campers Unveil Camp Coldie: The Ultimate Adventure Beer

Restaurants

Analyst Ratings

Tilray Brands Ranks #4 on the Brewers Association List of Top Producing Craft Brewers in the United States

Tilray Brands Announces Proposed Reverse Stock Split and Corresponding Special Meeting of Stockholders

Tilray Medical Introduces Cannabis Edibles in Australia

Tilray Beverages Launches Cruisies, a New Line of Ready-To-Drink Cocktails

Breckenridge Distillery Announces Re-Release of Award-Winning Cognac Cask Finish Whiskey

Terrapin Beer Co. Celebrates 23 Years of Craft Beer and Environmental Stewardship with Terraprint Initiative and Orvis Partnership

Opinion

Forget Sugary Sodas Wellness Drinks Are Gaining Ground With Consumers and Investors

Widmer Brothers Brewing Celebrates 40th Anniversary

10 Barrel Brewing Launches Non-Alcoholic Apocalypse IPA, a Bold Craft Brew for Your Next Adventure

Comments

Tilray Brands

Tilray Brands (TLRY) Opciones

Tilray Brands (NASDAQ:TLRY) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL